AI-assisted health education for people with blood cancers
Official title: The Impact of Artificial Intelligence-Assisted Health Education on Patients' Intention to Participate in Clinical Trials: A Cluster-Randomised Controlled Trial
Run by Zhongnan Hospital · NCT07305337 · Data updated 2026-11-12
This project tests whether an AI chatbot can improve awareness of clinical trials and willingness to join among adults with blood cancers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 196 (estimated) |
| Sponsor | Zhongnan Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | June 28, 2025 |
| Main results expected | August 28, 2026 |
| Study ends | August 30, 2026 |
| Registry record updated | December 26, 2025 |
| Trial ID | NCT07305337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) diagnosed with a hematologic malignancy who are conscious, able to understand and communicate, and willing to give informed consent are the ideal candidates.
✕Probably not a fit
Patients with significant cognitive impairment, severe psychiatric disorders, very short expected hospital stays, those receiving end-of-life palliative care, or those who have already completed other clinical trial education programs are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with hematologic malignancies who meet eligibility are randomly assigned to receive an AI-robot–delivered health education intervention or usual information. The intervention delivers standardized clinical trial information via an AI bot and measures changes in patients' knowledge, attitudes, and intention to participate. Outcomes are collected using questionnaires and intention measures before and after the intervention to compare groups. The study also examines feasibility and potential for scaling this AI-assisted education approach in routine care.
Why it matters
Potential benefit: If successful, the AI education approach could increase patient understanding of clinical trials and help more eligible patients consider joining them.
How similar studies have gone: Some digital and AI-driven education programs have improved patient knowledge and engagement, but AI-robot–delivered clinical trial education specific to blood cancers is relatively new with limited direct evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (1) Aged ≥18 years with clear consciousness; (2) Diagnosed with haematological malignancy meeting clinical treatment criteria (WHO criteria); (3) Capable of understanding health education content and possessing basic communication skills; (4) Willing to participate in this study and sign an informed consent form. Exclusion Criteria (1) Patients with concomitant cognitive impairment, psychiatric disorders, or other conditions severely affecting comprehension; (2) Anticipated hospital stay of less than 3 days, rendering completion of the intervention unfeasible; (3) End-of-life palliative care; (4) Previous participation in other clinical trial education programmes.
Where it's running
-
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Fuling Zhou
- Email: zhoufuling@163.com.cn
- Phone: 027-67813137
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Reduced‑dose apixaban or rivaroxaban versus daily low‑molecular‑weight heparin for people with blood cancers
This trial will test whether reduced‑dose apixaban or rivaroxaban pills can prevent blood clots as well and as safely as daily low‑molecular‑weight heparin injections in people with hematologic malignancies.
-
xDRIVE personalized tumor testing for Florida cancer patients
This program will try a functional precision medicine and AI platform (xDRIVE) to help guide next treatment options for Florida patients with recurrent or refractory cancer, including children and people from underserved communities.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD38-targeted PET/CT for detecting Multiple Myeloma lesions compared with FDG PET/CT
This study tests a CD38-targeted PET/CT scan to see if it detects multiple myeloma lesions as well or better than the standard FDG PET/CT.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.